Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bamzireotide navoxetan
- Development stage
- Unknown
- Lead developer
- Perspective Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Bamzireotide navoxetan (also known as [212Pb]VMT-α-NET) is an investigational, peptide-targeted alpha-particle radiopharmaceutical therapy developed by Perspective Therapeutics (originally originated by Viewpoint Molecular Targeting) for the treatment of somatostatin receptor subtype 2 (SSTR2)-expressing solid tumors, including neuroendocrine tumors (NETs) and meningiomas. The drug consists of a somatostatin analog peptide (bamzireotide) conjugated to a lead-specific chelator (navoxetan) via a linker, which coordinates the alpha-emitting radioisotope lead-212 (212Pb). Upon intravenous administration, the peptide selectively binds to SSTR2 overexpressed on tumor cells, delivering highly localized, high-energy alpha radiation that induces double-stranded DNA breaks and tumor cell death while minimizing damage to surrounding healthy tissues. It is currently being evaluated in Phase 1/2a clinical trials, with preparations underway for a registrational Phase 3 study.
- Other names
- bamzireotide + navoxetanlead (203Pb) bamzireotide navoxetanlead (212Pb) bamzireotide navoxetan
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on bamzireotide navoxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bamzireotide navoxetan.